article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

FDA Law Blog: Biosimilars

Indeed, since 2014, DPD facilitatedthe publication of 42 quarterly batches and dozens of stand-alone PSGs, plus three one-off batches of PSGs updated to align with recommendations in general guidance documents ( g. , Under GDUFA III alone, DPD published 32 GDUFA guidance documents and MAPPs to ensure the successful implementation of GDUFA.

article thumbnail

Drug Storage

RX Note

Read and document refrigerator and freezer temperatures at least twice each workday (in the morning and before the end of the workday). An example of a buffered probe is one immersed in a vial of liquid (e.g. This prevents false readings due to the rapid changes in air temperature that occur when refrigerator doors are opened.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Renal Drug Dosing References

RX Note

Demystifying Drug Dosing in Renal Dysfunction, 2019 Demystifying Drug Dosing in Renal Dysfunction serves as a quick reference for commonly used medication dosing given varying degrees of renal dysfunction and/or use of renal replacement modalities.

article thumbnail

Beyond instruments: streamlining process technology implementation in biopharmaceutical manufacturing

European Pharmaceutical Review

To give examples, such a work package focuses on the identification of regulations (ICH Q2 R2, 3 Q8-Q14, 4-10 FDA PAT guidance, 11 EMA Annex 15 12 ), some of which may be mainly guidance documents with recommendations and flexibility when it comes to PAT.

article thumbnail

Addressing US FDA challenges in Indian sterile drug manufacturing – Part 3

Express Pharma

Archive design basis documents for all facility, process, and utility decisions. Treat each deviation, complaint, or EM excursion as a rehearsal for an FDA discussion – document decisions, risk rationales, and CAPAs with inspection-grade clarity. Regularly conduct mock inspections using external or cross-site auditors.

article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. Annual health-related costs related to PFAS across Europe are estimated at up to 4.6 www.eea.europa.eu. Available from: [link] Goldenman G, Fernandes M, Holland M, et al.

article thumbnail

Pharmacist to Clinical Strategy Leader: Brendan Doran on Building a Career in Biotech

The Nontraditional Pharmacist

So, we would have spoken in 2019. And then how do you develop documents to basically get approval from the FDA to study your drug in humans? The last time we spoke, biosimilars were this new thing and everyone was trying to figure out what was going to happen regulatory-wise and a lot of other changes since then. It’s 2025.